start-loss, VAF 8% as variants of strong or potential clinical significance (Diagnostic, Prognostic & Therapeutic) TIER 1/2, which are commonly seen in association with the BCL2-R-negative, CD23+ follicle center lymphoma. Here, BCL2 is linked to follicular lymphoma.